UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response..

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

			` '			•	•								
(Print or Ty	pe Respons	es)													
1. Name and Address of Reporting Person – HUCKEL HUBERT E MD (Last) (First) (Middle) C/O TITAN PHARMACEUTICALS			Symbol TITAN PHA [TTP] 3. Date of Earl	TITAN PHARMACEUTICALS INC [TTP] 3. Date of Earliest Transaction					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% OwnerOfficer (give titleOther (specify below)			elow)			
	OYSTER	08/09/2005	(Month/Day/Year) 08/09/2005												
S SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Sta	ate) (Zip)	Table I - N	on-Deriv	vativ	ve Securit	ties A	Acquired, D	isposed of, or	Beneficially	Owned				
1.Title of S (Instr. 3)	D	Date Month/Day/Year)	Month/Day/Year)	ransactio Code Instr. 8)	n A		(A) of (D) and (A) or	or Securi 0) Benef 5) Follow Transa	ount of tities icially Owned wing Reported action(s) 3 and 4)	6. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4)	Benefi Owner	rect cial ship			
directly or	indirectly.		erivative Securities g., puts, calls, warr	Acquire	info req cur d, D	ormation uired to rently va Disposed o	cor resp alid	ntained in t pond unles OMB contr r Beneficiall	he collection his form are s the form d ol number. y Owned	not	SEC (9	1474 0-02)			
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb		6. Date Exe	rcisable and	7. Title and	Amount	8. Price of	9. Number of	10.	11. Nature
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	e (Month/Day/Yea	Execution Date, if	Transaction Code (Instr. 8)		n of			xpiration Date Month/Day/Year)		of Underlying Securities (Instr. 3 and 4)		Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right	\$ 2.05	08/09/2005		A		15,000		<u>(1)</u>	08/09/2015	Common Stock	15,000	\$0	15,000	D	

Reporting Owners

Denouting Orange Norma / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
HUCKEL HUBERT E MD							
C/O TITAN PHARMACEUTICALS INC	X						
400 OYSTER POINT BLVD	Λ						
S SAN FRANCISCO, CA 94080							

Signatures

to Buy)

/s/ Hubert E. Huckel	08/10/2005
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) These options vest in equal installments over a 12-month period commencing on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.